Is there an official retatrutide dosing schedule?
The short answer is no. Retatrutide is still being tested. It has not been approved by the FDA (the part of the US government that checks whether a medicine is safe and actually works). Because no one has approved it, there is no official dose and no official schedule to follow.
It is what scientists call investigational. That word just means "still being studied." Right now the only place retatrutide is used is inside clinical trials — careful research studies where doctors give the medicine, watch closely, and write down everything that happens.
So when people search for "the retatrutide dosing schedule," there is an honest answer: there is not one for the public. What does exist is the schedule the researchers use inside those trials. That is what the rest of this page explains — not as a plan for you to copy, but so you can understand what the studies are doing. Any actual schedule for a real person is decided by a trial protocol or a doctor, never by a web page.
It helps to keep two ideas separate. An "approved schedule" is the official dose printed on a medicine's label after regulators have reviewed all the evidence — that is what your pharmacist follows for an approved drug. A "trial schedule" is just the plan researchers chose to test in one specific study. Retatrutide only has the second kind. Reading about it is fine; treating it as a personal prescription is not, because it was never written for you.
What is retatrutide, and why does its design shape the schedule?
Before the schedule makes sense, it helps to know what retatrutide actually is. It is a man-made medicine that copies three of your gut's natural "I have eaten" messages at once — signals called GIP, GLP-1, and glucagon. Most weight-loss shots copy one or two of these messages; retatrutide copies all three. In the lab work that first described it, scientists called it a "triple agonist," which simply means one molecule that switches on three receptors instead of one.
That three-in-one design is the whole reason researchers built it the way they did. Each of those three signals nudges the body a little differently — some quiet hunger, some help the body handle sugar, and one (glucagon) is thought to nudge how the body burns fuel. Combining them is the experiment. It is also why the medicine is being tested so carefully: a stronger, broader effect has to be introduced gradually and watched closely.
It is worth naming what each of the three signals roughly does, because together they explain the design. GLP-1 is the best-known of the group — it is one of the gut's main "I am full" messengers and also helps the body release insulin after a meal. GIP works alongside it on how the body handles food and sugar. Glucagon, the third, is involved in how the body mobilizes and burns stored fuel. Researchers have studied GLP-1 in particular for years, which is part of why a medicine built around these signals could be reasoned about carefully before it was ever given to a person.
The design also shaped how often it is given. When the molecule was first studied, its makers found it stayed active in the body for a long time after a single dose — long enough to support a once-a-week rhythm rather than a daily one. So the "schedule" you are curious about is not arbitrary. It flows directly from what the molecule is and how long it lasts, both of which were measured in early research, not guessed.
How is it dosed in the clinical trials?
In the main study so far — a Phase 2 obesity trial published in 2023 — retatrutide was given as a small injection under the skin, once a week. "Under the skin" is the medical term subcutaneous, the same kind of shot used for other weekly weight medicines.
The doctors did not start people at a big dose. They started low and worked up slowly over several weeks. This step-by-step build-up has a name: titration. It simply means raising the dose a little at a time instead of jumping straight to the top. In that trial the doses studied went up to levels of 1, 4, 8, and 12 milligrams a week, depending on which group a person was in, and different groups began their climb from a gentle 2 mg or 4 mg starting point.
A separate Phase 2 study tested retatrutide in adults with type 2 diabetes, again as a once-weekly injection with the same slow build-up. The fact that two different trials, in two different groups of people, both used a weekly shot with gradual titration tells you this rhythm is a deliberate, repeated design choice — not a one-off.
So the trial "schedule" is really two ideas put together: the same day every week for the injection, and a dose that climbs gradually until it reaches the target the study picked for that group. Again, those exact numbers belong to the study. They are not a recommendation, and no one should treat them as one.
What did the trials measure at each dose?
People often ask what the different dose levels actually did, so here is what the research reported — strictly as study results, not as a reason to chase a number. In the Phase 2 obesity trial, average weight change at 48 weeks rose with the dose: roughly 9% lower at the 1 mg level, about 17% at 4 mg, about 23% at 8 mg, and about 24% at the highest 12 mg level. In the separate diabetes study, the highest dose group saw around 17% body-weight reduction along with meaningful improvements in long-term blood sugar.
There is an important pattern hiding in those numbers. The jump from low to middle doses was large, but the gap between the two highest doses was much smaller. That kind of "leveling off" is exactly why researchers test several doses instead of assuming more is always better — they are looking for the point where benefit and side effects balance out.
It is worth repeating the obvious: these figures come from monitored studies in selected volunteers, paired with regular check-ins and lab work. They are a description of what happened in a trial, not a target for anyone to aim at on their own. The honest takeaway is about how careful dose-testing works, not about which number to want.
| Weekly dose | Average weight change at 48 weeks |
|---|---|
| 1 mg | About −9% |
| 4 mg | About −17% |
| 8 mg | About −23% |
| 12 mg | About −24% |
Why raise the dose slowly?
Starting low and building up is on purpose. Think of it a bit like easing into very hot water instead of jumping in — you give your body time to adjust.
The most common side effects with this kind of medicine are stomach ones: feeling a little sick, an upset belly, or going to the bathroom more. These tend to show up most when the dose first goes up, and they often settle as the body gets used to it.
The researchers actually saw this play out. In the trial, using a gentler lower starting dose of 2 milligrams led to fewer stomach side effects early on than starting higher. That is the whole point of titration: a slow climb gives the gut time to adapt, so more people can keep going and reach the dose the study is testing without feeling rotten along the way.
This is also a safety habit shared across this whole family of medicines, not something unique to retatrutide. The approved weekly weight and diabetes shots are stepped up the same gradual way. When researchers design a brand-new medicine, copying that slow-and-steady pattern is a way of being cautious with something that has not finished testing.
Why once a week?
Once a week sounds unusual for a medicine, but it is by design. Retatrutide is built to be long-acting — that means one dose keeps working for days instead of wearing off in hours.
This copies how the approved weekly weight and diabetes shots already work. Your body's own gut signals, like GLP-1, normally fade within minutes once they are released. These medicines are engineered to last far longer, so a single weekly shot can keep the "I am full" signal switched on across the whole week.
There is real measurement behind the weekly choice. In the early research that first described retatrutide, a single dose was still lowering body weight more than a month later — its effect lingered for weeks, not hours. A medicine that lasts that long simply does not need a daily routine, and dosing it daily would risk stacking too much on board. So the trials settled on a once-a-week rhythm that matches how long the molecule actually stays active.
This is not medical advice
It is worth saying plainly: nothing on this page is medical or dosing advice, and it is not a how-to. Retatrutide is not approved, you cannot get a prescription for it as an approved medicine, and the doses above come from research studies — not from a recommendation for any individual.
The next big set of studies, called the TRIUMPH program, is a group of larger Phase 3 trials still underway — four trials enrolling more than 5,800 people, looking not just at obesity but at related conditions like sleep apnea and knee arthritis. Phase 3 is the late-stage testing a medicine goes through before regulators decide whether to approve it. Because that work is still going, retatrutide remains investigational and still has no approved schedule.
One more reason the "schedule" cannot be copied from a page: the trial numbers are group averages, chosen and adjusted for the specific people enrolled and watched closely the whole way. A real person's right starting point, how fast to climb, and where to stop depend on their health, their other medicines, and how they respond — judgments only a clinician can make in context. A fixed schedule lifted off the internet ignores every one of those variables.
If you are curious about retatrutide, the right next step is a conversation with a licensed clinician — and, if it ever becomes relevant, an official clinical trial. A trained doctor or a trial protocol is the only proper source for any dose or timing. A search result is not.
Tracking a protocol with PeptidePanel
PeptidePanel does not sell, supply, prescribe, or recommend retatrutide or any other medicine. It is simply a tracking tool. The dosing details on this page exist only inside research studies, and any real plan comes from a clinician or a trial.
If a clinician has set up a protocol for someone — for any medicine — keeping track of it is where a tool like this helps. It records the plan a doctor set, notes which step of a slow dose build-up a person is on, charts weight and lab numbers over time, and reminds them when something is due. Think of it as a tidy, date-stamped notebook for the doctor's plan, so every check-in has the full picture to work from.
That kind of record is most useful precisely because medicines in this family are stepped up gradually and watched over months. A clear log of "which week, which step, how it felt, what the labs showed" gives the clinician — the person actually making the decisions — a complete history to work from. The tool keeps the notes; the doctor keeps the call.